Critical Appraisal of Extended Treatment Studies in Attention-Deficit Hyperactivity Disorder
Dear Editor:
Russell Schachar and colleagues' excellent review (1) offers a sobering and necessary balance that illustrates the current limitations of our knowledge regarding treatment effects in attention-deficit hyperactivity disorder (ADHD). With regard to the combination of pharmacologic and nonpharmacologic treatment approaches, it is instructive to note that the literature does not address an important practical issue for children responding to short-term stimulants in the classroom. We know that most treatment studies have found positive benefit for short-acting stimulants, even though these medications give a benefit for only 90 minutes, approximately. Why these short-acting medications work as well as they do throughout the school day, given their short duration of action, is an important and relatively unexplored question.
A recent article on impulse disorders casts light on this question (2) . In it, Strayhorn makes the point that one aspect of working with impulse disorders concerns facilitating the development of "a positive momentum." Perhaps this is an important clue as to why the short-acting medications work as well as they do. In theory, the longer-acting stimulants provide better coverage throughout the school day; however, many children do receive good benefit from short-acting preparations-a seeming paradox. This suggests that the sustained action of these short-acting medications might be explained in terms of the development of positive momentum. If children with ADHD "get on track" for 90 minutes at the beginning of the morning and afternoon school, their positive momentum may carry them along for the remaining time. If children are more able to achieve success in the class, albeit for a short period, their self-cognitions are more likely to be positive than negative. Perhaps this is the underlying mechanism behind the sustained benefit of short-acting medications beyond their pharmacologically effective time window. If so, facilitating positive momentum with cognitive and behavioural techniques begins to make more sense. The interaction wherein the pharmacologic effects of a short-acting stimulant allow the teacher to help the child get on a positive track may be a fruitful source of further research investigating how teachers can help children with ADHD enter the learning group.
Schachar's article notes that currently available randomized treatment studies have some significant limitations regarding the wide array of outcomes that are important to measure for children and adolescents with this common disorder. An important and underexplored outcome is related to public health-driving safety and ADHD. Recent research emphasizes the increased risk of dangerous driving behaviour in young drivers with ADHD and other impulse disorders (3) . Ongoing research in this very important area of impulsivity and dangerous driving raises the possibility of identifying highrisk groups early and developing early preventive intervention strategies for an underrecognized public health issue.
Gabapentin-Induced Paradoxical Exacerbation of Psychosis in a Patient With Schizophrenia
Gabapentin is an anticonvulsant that is increasingly prescribed to patients with schizophrenia (1) . Uses of anticonvulsants in this population have traditionally included antipsychotic augmentation and control of aggression and impulsivity (1) . Gabapentin is reported to have antianxiety and hypnotic effects in patients with schizophrenia (2) and panic disorder (3). Documented behavioural side effects include hypomanic and manic mood changes, aggression, and agitation (4-6). We report a case of paradoxical worsening psychosis associated with initiation of gabapentin in a patient with schizophrenia.
Mr A, aged 23 years, was diagnosed at age 18 years with schizophrenia according to DSM-IV criteria. He has permanent, full-time employment. His medications prior to starting gabapentin included clozapine 425 mg daily, procyclidine 10 mg daily, divalproex sodium 1000 mg daily, and fluoxetine 30 mg daily. He has been maintained on divalproex sodium since his initial presentation for affective symptoms. Fluoxetine was added to alleviate medicationinduced obsessive-compulsive symptoms. No recent medication changes have been made. His baseline psychotic symptomatolgy included rare paranoid ideation and rare auditory hallucinations. He presented with complaints of decreased sleep, and gabapentin therapy was initiated at 300 mg nightly. After 4 days, he noted increased paranoid ideation, increased auditory hallucinations, and racing thoughts. Although his sleep significantly improved with gabapentin, worsening psychosis necessitated 2 days off work. He stopped the medication after 4 days and noticed a gradual decrease in symptoms over the following 8 days. He denied concomitant alcohol or drug use and was compliant with medication. He was seen 2 weeks after starting gabapentin therapy and judged to be at baseline.
We propose 2 possible mechanisms to explain our observation. First, gabapentin is a structural analog of the inhibitory neurotransmitter GABA (7) . Like benzodiazepines, gabapentin is a GABAenhancing drug (7) . Paradoxical worsening of psychotic symptoms has been documented in schizophrenia patients treated with benzodiazepines (8) . Paradoxical aggravation of psychosis by gabapentin may occur through a similar mechanism. Alternatively, gabapentin is known to interfere with amino acid uptake across cell membranes (7) . By interfering with clozapine transport across membranes, gabapentin may cause an acute decrease in cerebrospinal fluid or intracellular clozapine, leading to paradoxical psychosis. However, this effect appears rare, because gabapentin with clozapine has been given to schizophrenia patients, with therapeutic benefits (2, 9) . Karin Jablonowski MD, CM Howard C Margolese MD, CM, FRCPC Guy Chouinard MD, MSc, FRCPC Montreal, Quebec
Probable Dementia With Lewy Bodies and Risperidone-Induced Delirium
To date, there have been few reports of delirium induced by risperidone, a benzisoxazole derivative that is one of the atypical antipsychotics. One study reported that, of 122 elderly persons treated with risperidone, 2 developed delirium (1.6%) (1) . There is also a case report of delirium probably induced by risperidone (2) . In a few cases, delirium was induced by combined lithium and risperidone (3) . We report a case of probable dementia with Lewy bodies (DLB) that was likely induced by risperidone.
Mr A, aged 82 years, was introduced to our university hospital from a general hospital for the treatment of visual hallucinations and aggressive behaviour to surrounding persons. One year previously, he had been treated by tiapride 100 mg and amantadine 100 mg daily for aggressive behaviour and parkinsonism. His mental state fluctuated and gradually deteriorated. In addition to his chief complaints, he also had moderate dementia and experienced repeated falls and transient loss of consciousness. From the above symptoms, he satisfied the consensus criteria for the clinical diagnosis of probable DLB, according to guidelines published in 1996 (4) . He also had the following physical disorders: hepatocellular carcinoma, mild chronic renal dysfunction (his serum urea was 27 mg/dl and his creatinine was 1.3 mg/dl), and gallstones.
He was started on risperidone 1 mg daily in the evening of his examination day. By the next morning, he showed a state of extreme excitement. He brandished his cane wildly, and he shouted, "Water has been heavily sprinkled inside my house. A strange woman is coming. There is a rat in the clock." His symptoms had subsided by the evening of the day 2, and he did not remember his excited behaviour. After his family stopped risperidone, his behaviour returned to what it was on the day of the examination. On day 3, he was started on haloperidol 1.5 mg daily instead of risperidone. His aggressive behaviour gradually diminished, and haloperidol was reduced (0.75 mg daily). On day 14, he was given additional medication of donepezil to treat his visual hallucinations. After 3 weeks, the visual hallucinations had greatly decreased.
Risperidone has recently been used in Japan to treat delirium and paranoid hallucinations in elderly persons. However, it is necessary to carry out more careful observation when risperidone is used to treat patients with probable DLB.
